Volume 1, Problème 2 (2011)
Prospective Thérapeutique
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
Article de révision
Diagnosis and treatment of prostate cancer-related bone disease
Tilman Todenhoefer, Georgios Gakis, David Schilling, Gerhard Feil, Christian Schwentner,Arnulf Stenzl
Article de révision
Tyrosine kinase inhibitors in differentiated thyroid arcinoma: a review of the clinical evidence
Hendrieke C Hoftijzer, Ellen Kapiteijn2, Tatiana, Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom, Johannes WA Smit
Article de révision
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Article de révision
Cladribine in the treatment of multiple sclerosis
Karen Schreiber, Per Soelberg Sorensen
Article de révision
Emerging treatments for small-cell lung cancer: Phase II and III trials
Joel W Neal, Matthew A Gubens, Heather A Wakelee
Article de révision
Clinical efficacy and safety of moroctocog alfa
Emanuela Marchesini, Domenico Prisco, Alfonso Iorio
Article de révision
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
Article de révision
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
Article de révision
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Prospective Thérapeutique
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
